It has been recently documented that PI3K inhibitors were the most effective in inhibiting leukemic cell proliferation and survival in a panel of T-ALL human cell lines, irrespectively of PTEN status. This evidence concerns the gene PIK3CD and acute lymphoblastic leukemia.